CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB003

Vitamin D Testing (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D) Coverage Criteria

Laboratory reimbursement and coverage criteria for serum vitamin D testing (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D) for Blue Cross Blue Shield of Oklahoma members; affects providers submitting claims for these tests.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyVitamin D Testing (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D) Coverage Criteria

Policy CodePolicy CPCPLAB003

Change TypeRevised (reimbursement information and literature review updated)

Effective DateJun 15, 2023

Next Review Date

Key ActionVerify plan benefits and product-specific coverage requirements before ordering vitamin D testing and submit accurate documentation to support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Reimbursement information revised for clarity and literature review updated.

3procedural CPT/HCPCS codes listed

12wminimum interval after supplementation

2/yrmax monitoring tests per year

6/15/23Plan effective date

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Medically Necessary Indications

Covered when ANY of the following indications apply:

25-hydroxyvitamin D - diagnostic or monitoring: Serum 25-hydroxyvitamin D testing is reimbursable for individuals with an underlying disease or condition specifically associated with vitamin D deficiency or decreased bone density (see Note 1) or for individuals suspected of hypervitaminosis D; fractionation into D2 and D3 may be reimbursable as part of total 25-OH D analysis.

See Note 1 for detailed list of qualifying conditions

Repeat testing after documented deficiency: For individuals with documented vitamin D deficiency, repeat serum 25-hydroxyvitamin D testing is reimbursable at least 12 weeks after initiation of supplementation, with monitoring testing not to exceed 2 instances per year until the therapeutic goal is achieved; once therapeutic range is reached, annual testing may be reimbursable.>=12 weeks; <=2/year until goal; annual thereafter

1,25-dihydroxyvitamin D - metabolic disorders: Serum 1,25-dihydroxyvitamin D testing is reimbursable for evaluation or treatment of conditions associated with defects in vitamin D metabolism (see Note 2).

See Note 2 for qualifying conditions

Serum testing for 1,25-dihydroxyvitamin D is intended for evaluation or management of conditions that suggest a defect in vitamin D metabolism (see Note 2). It is not the preferred test to assess routine vitamin D status; 25-hydroxyvitamin D is the standard assay for identifying deficiency and monitoring supplementation. Coverage for vitamin D testing is limited to the medically necessary indications described in this policy and is not intended to support population-wide screening.

The following uses are explicitly not medically necessary and are not reimbursable: routine population screening for vitamin D deficiency in asymptomatic individuals or the use of 1,25-dihydroxyvitamin D as a screening test for vitamin D deficiency.

Specific Covered Indications

inv-14: Conditions specifically associated with vitamin D deficiency or decreased bone density

Conditions specifically associated with vitamin D deficiency or decreased bone density (Note 1):

Note 1 - qualifying conditions list: Biliary cirrhosis and other specified disorders of the biliary tract; Blind loop syndrome; Celiac disease; Coronary artery disease when considering chronic vitamin D and calcium therapy; Dermatomyositis; Eating disorders; Bariatric procedures (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy, biliopancreatic diversion with or without duodenal switch); Hypercalcemia or hypocalcemia and other disorders of calcium metabolism; Hyperparathyroidism or hypoparathyroidism; Individuals receiving hyperalimentation; Intestinal malabsorption; Liver cirrhosis; Long-term use of anticonvulsants, glucocorticoids, or other medications known to lower vitamin D levels; Malnutrition; Myalgia and other myositis; Myopathy related to endocrine diseases; Neoplastic hematologic disorders; Obesity; Osteogenesis imperfecta; Osteomalacia; Osteopetrosis; Osteoporosis; Pancreatic steatorrhea; Primary or miliary tuberculosis; Psoriasis; Regional enteritis; Renal, ureteral, or urinary calculus; Rickets; Sarcoidosis; Stage III-V chronic kidney disease and end stage renal disease; Systemic lupus erythematosus.

Full list of qualifying conditions provided in Note 1

inv-15: Conditions associated with defects in vitamin D metabolism where 1,25-dihydroxyvitamin D testing is appropriate

Conditions associated with defects in vitamin D metabolism where 1,25-dihydroxyvitamin D testing is appropriate (Note 2):

Note 2 - qualifying conditions list: Disorders of calcium metabolism; Familial hypophosphatemia; Fanconi syndrome; Hyperparathyroidism or hypoparathyroidism; Individuals receiving hyperalimentation; Neonatal hypocalcemia; Osteogenesis imperfecta; Osteomalacia; Osteopetrosis; Primary or miliary tuberculosis; Renal, ureteral, or urinary calculus; Rickets; Sarcoidosis; Stage III-V chronic kidney disease and end stage renal disease.

Full list of qualifying conditions provided in Note 2

inv-16: Suspected hypervitaminosis D (high importance)

Suspected hypervitaminosis D:

Suspected hypervitaminosis D: Serum 25-hydroxyvitamin D testing may be reimbursable for individuals suspected of hypervitaminosis D.

Procedure Codes and Coding Guidance

Procedure codes referencedCPT|HCPCS|mixed

82306	25-Hydroxyvitamin D; includes quantitation of total 25-OH D
82652	1,25-Dihydroxyvitamin D
0038U	Vitamin D, 25-hydroxy, includes fractionation of D2 and D3 (proprietary/other)

inv-05: Repeat testing interval after supplementation — at least 12 weeks

Minimum interval after starting supplementationRepeat serum 25-hydroxyvitamin D testing allowed at least 12 weeks after initiation of vitamin D supplementation.

Context for repeat testingApplies to individuals with documented vitamin D deficiency.

Related restrictionRepeat testing for monitoring should not exceed frequency limits (see monitoring frequency).

inv-06: Monitoring frequency until therapeutic goal — no more than 2 tests per year

Maximum monitoring frequency until goalMonitoring testing should not exceed 2 testing instances per year until the therapeutic goal is achieved.

Applies toIndividuals undergoing supplementation for documented vitamin D deficiency.

After goal achievedOnce therapeutic range is reached, annual testing may be reimbursable (see frequency limits).

Testing Frequency and Repeat Interval

inv-17: 25-hydroxyvitamin D — No more than 2 monitoring tests per year until therapeutic goal is achieved; thereafter annual testing may be reimbursable.

Monitoring limitNo more than 2 monitoring tests per year until therapeutic goal is achieved; thereafter annual testing may be reimbursable.

Test referencedSerum 25-hydroxyvitamin D.

Applies whenUsed for monitoring supplementation in individuals with documented deficiency.

inv-18: 25-hydroxyvitamin D — Repeat testing allowed at least 12 weeks after initiation of supplementation.

Repeat testing intervalRepeat serum 25-hydroxyvitamin D testing is allowed at least 12 weeks after initiation of vitamin D supplementation.

PopulationIndividuals with documented vitamin D deficiency.

PurposeTo assess response to supplementation prior to further monitoring.

Provider Actions and Documentation Requirements

Note

Verify coverage before testing

Coverage governed by the policy's reimbursement criteria. Verify member benefits and any product-specific requirements (including prior authorization, benefit limits, and provider contract terms) before ordering vitamin D testing to ensure services are eligible for reimbursement.

Affected codes: 82306, 82652, 0038U

Documentation Required

Documentation and medical necessity

Providers are responsible for submitting accurate and complete documentation to support medical necessity for testing. Claims may be audited and providers may be asked to supply additional clinical records, test indications, and treatment plans.

Denial Risk

Denial risk for non-covered indications

Do not use serum 1,25-dihydroxyvitamin D testing for routine screening of vitamin D deficiency; claims for this indication may be denied.

Not reimbursable: measurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D deficiency
Not reimbursable: routine screening in asymptomatic individuals or during general encounters

Billing Rule

Follow reimbursement criteria for testing and repeat monitoring

As outlined in the reimbursement guidance, 25-hydroxyvitamin D testing is reimbursable when there is an underlying disease/condition associated with deficiency or suspicion of hypervitaminosis D; repeat testing for documented deficiency is allowed no more than twice per year until therapeutic goals are reached and thereafter annually. Ensure documentation supports timing and indication for repeat tests.

Reimbursement conditions: underlying disease/condition associated with deficiency; suspected hypervitaminosis D
Repeat testing: ≥12 weeks after initiation of supplementation; ≤2 tests/year until goal achieved; annual testing once therapeutic range reached
D2/D3 fraction testing may be reimbursable as part of total 25-hydroxyvitamin D analysis

Ordering and Submission Requirements

Billing Rule

ORDERING REQUIREMENTS

Before ordering, verify product-specific coverage in plan documents; ensure the indication is accurately documented on the claim and be prepared to supply additional documentation upon request.

Confirm that the patient's condition matches reimbursable indications (e.g., Note 1 conditions for 25‑OH D or Note 2 conditions for 1,25‑dihydroxyvitamin D).
For repeat 25‑hydroxyvitamin D testing, document that testing is at least 12 weeks after starting supplementation and that monitoring frequency does not exceed 2 tests per year until goal is reached.

Definitions

inv-12: 25-hydroxyvitamin D — serum test to assess vitamin D status and monitor supplementation

Intended useSerum 25-hydroxyvitamin D is the test to assess vitamin D status and to monitor supplementation therapy.

FractionationTesting for D2 and D3 fractions as part of total 25-hydroxyvitamin D analysis may be reimbursable.

Reimbursable indicationsIndividuals with underlying disease/conditions associated with vitamin D deficiency or suspected hypervitaminosis D.

inv-13: 1,25-dihydroxyvitamin D — active metabolite measured when disorders of vitamin D metabolism are suspected; not appropriate for screening

Test purpose1,25-dihydroxyvitamin D measures the active metabolite and is used when disorders of vitamin D metabolism are suspected.

Not for screeningMeasurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D deficiency is not reimbursable.

Appropriate indicationsReimbursable for evaluation or treatment of conditions associated with defects in vitamin D metabolism (see Note 2 for examples such as disorders of calcium metabolism, familial hypophosphatemia, Fanconi syndrome, hyper/hypoparathyroidism, CKD stage III-V, sarcoidosis, rickets, etc.).